Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.
- March 31, 2023
During an individual stay in the Intensive Care Unit (ICU), sepsis is identified in 29.5% of patients,² with high mortality rates for those with bloodstream infections (BSIs) that range from 26% to 47%.³
Blood cultures are routinely ordered for sepsis patients in the ICU, but they have certain limitations, including inconsistent results due to slow growth⁴, interference from previously administered antimicrobials, and difficulty with identifying polymicrobial infections.⁵
T2 Biosystems has developed the first and only diagnostic test panels to provide species identification directly from a whole blood sample without waiting for a positive blood culture. The T2Bacteria® and T2Candida® Panels are run on the fully automated T2Dx® Instrument and are powered by T2 Magnetic Resonance (T2MR®) Technology.
With results in as little as 3 to 5 hours, physicians can target therapy before the second dose of empiric therapy has been administered. When every hour counts, T2Bacteria and T2Candida can provide rapid species identification for bacterial and fungal infections before the blood culture turns positive, enabling timely and targeted treatment for better patient outcomes.